ASCO News From Genentech

Genentech medicines that represent progress in targeted medicines and immunotherapies:

  • Alectinib, pivotal data showing the investigational ALK inhibitor shrank tumors in about half of the people with advanced ALK-positive non-small-cell lung cancer (NSCLC) following treatment with crizotinib [press release].
  • Atezolizumab (MPDL3280A; anti-PDL1), data showing the investigational cancer immunotherapy reduced the risk of death by half in advanced NSCLC [press release].
  • Cobimetinib data showing the investigational MEK inhibitor helped people with advanced BRAF-mutated melanoma live for a year without disease progression [press release].
  • Gazyva®(obinutuzumab) data showing the anti-CD20 antibody helped double the time before disease progression in people with indolent non-Hodgkin’s lymphoma who stopped responding to a standard of care [press release].
  • Perjeta® (pertuzumab) data showing the medicine helped reduce the risk of disease progression, recurrence or death when used prior to surgery by people with HER2-positive early breast cancer.  [press release].
Viewpoints from the cancer community on hot topics at ASCO, which are available at There are patient perspectives on living with cancer, discussions of clinical trial trends, interactive tools on cancer immunotherapy, and much more.

No comments have been posted yet.